Neoleukin Therapeutics, Inc. (NLTX) News
Filter NLTX News Items
NLTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NLTX News From Around the Web
Below are the latest news stories about NEOLEUKIN THERAPEUTICS INC that investors may wish to consider to help them evaluate NLTX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayPre-market stock movers are rising and falling on Thursday as we check out all of the latest news worth knowing about this morning! |
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. |
BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncFirm real-time pick highlight |
Neurogene and Neoleukin Announce Definitive Merger AgreementProposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene’s differentiated portfolio of genetic medicines for complex neurological diseases Combined company is expected to have a cash balance of approximately $200 million at close, including approximately $95 million from concurrent private financing by Neurogene’s new and existing investors Cash expected to fund combined company into 2H:26 and through multiple catalysts, including preliminary data in 4Q:24 and addit |
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring PlanNeoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce. |
Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Neoleukin Therapeutics Seeks Strategic Alternatives, To Layoff More In Round 2 Within 6 MonthsNeoleukin Therapeutics Inc (NASDAQ: NLTX) has engaged SVB Securities to assist in reviewing strategic alternatives. Neoleukin also approved a further corporate restructuring to preserve cash, including reducing its workforce by approximately 70%. After a short transition, Chief Executive Officer Jonathan Drachman will also be stepping down. The company expects this reduction in force to be completed during the first half of 2023. "The work that Neoleukin has done to advance the science of de nov |
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership TransitionSEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value. Such alternatives may include a sale, merger, divestiture of assets, licensing or other strategic transaction. There can be n |